Аннотация:
The production of the analgesic peptide HCRG21 for medical use is restricted by a number of limitations in the technology. The optimal biotechnological method scalable to industrial has been developed based on the production of a fusion protein containing a special leader, His-tag, and Smt3 sequence upstream in the peptide sequence. The resulting peptide shared its inhibitory activity to TRPV1 ion channel identical to the published early.
Ключевые слова:
analgesic peptide, biotechnology, SUMO fusion, production in prokaryotes, fluorescence imaging, TRPV1 ion channel.